Immunotherapy Combination Improves Melanoma Outcomes, But at a Cost – Curetoday.com
Targeted Oncology |
Immunotherapy Combination Improves Melanoma Outcomes, But at a Cost
Curetoday.com Pre-surgical (neoadjuvant) treatment with the immunotherapy combination Opdivo (nivolumab) plus Yervoy (ipilimumab) nearly tripled objective response rates (ORR) in patients with high-risk resectable melanoma, compared to single-agent therapy with the … Nivolumab/Ipilimumab Combo May Hold Potential in Neoadjuvant Melanoma |
